Methods: We performed an observational cohort study within the Finnish Prostate
39-2
8% reduction in the 7-year prevalence of prostate cancer among patients treated with finasteride (5 mg daily) compared with that among patients treated with placebo; however, a 25
The only FDA-approved dermatological indication of
Methods: Data are from 10,057 participants in Prostate Cancer Prevention Trial (PCPT), a randomized trial of finasteride for primary prevention of prostate cancer
[1][2] This amounted to 1,414,249 newly diagnosed cases and 375,000 deaths worldwide yearly from this disease in 2020
A wide interindividual variation in response exists and is thought to be due to heritable factors
A central pathology review was performed in a blinded manner comparing these patients with 56 matched controls and 44 patients who received a 3-month course of LHRH agonist before radical prostatectomy
At trial's end, there was a 25% reduction in period prevalence in all prostate cancers (24
[1] ] report an interesting—and novel—reduction of bladder cancer risk in men from the Prostate, Lung, Colon, and Ovarian (PLCO) cancer screening trial who used finasteride
The first study on topical finasteride in humans was completed in 1997 by Mazarella et al
27 Sexual dysfunction was studied in over 17,000 patients during a 7-year period
In 2003 Thompson and colleagues reported that daily use of finasteride reduced the prevalence of prostate cancer by 25% compared to placebo
Yet the use of finasteride remains low, likely because of the risk of adverse effects